Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination topical formulation containing **acetyl zingerone** (AZ), a next-generation antioxidant, and **tetrahexyldecyl ascorbate** (THDC/THDA), a stable, lipid-soluble vitamin C prodrug. THDC/THDA enhances epidermal and dermal penetration and delivers vitamin C into the skin, supporting collagen synthesis and skin brightening. On its own, THDC/THDA is unstable under oxidative stress, has poor standalone antioxidant efficacy, and can induce pro-inflammatory gene activation, but co-formulation with AZ preserves THDC from degradation, neutralizes pro-inflammatory effects, and synergistically improves antioxidant activity, collagen production, photoprotection, and reduces wrinkle severity, pigmentation, and erythema. Mechanistically, AZ stabilizes THDC against oxidative degradation, suppresses activation of type I interferon and STAT1 pathways, and upregulates genes related to skin barrier and repair. The combination shows superior clinical efficacy for **photoaging** and pigmentation versus THDC alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetyl zingerone + tetrahexyldecyl ascorbate.